Entresto (sacubitril/valsartan) - Novartis, ROVI Pharmaceuticals Laboratories
Prognostic effect of polypharmacy in ambulatory patients with heart failure: a machine learning-based analysis. (PubMed, BMC Cardiovasc Disord) - Sep 27, 2026 - "High polypharmacy is associated with reduced long-term survival in patients with heart failure. This highlights the need for personalized prescribing strategies to minimize the risks associated with polypharmacy while maximizing therapeutic benefits." 
Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure
http://www.ncbi.nlm.nih.gov/pubmed/42800872
 
Babak Mohammadi; Houshang Bavandpour Karvane; Sepehr Nemati; Zahra Hooshanginezhad
 
Sep 27, 2026
 
Prev Next